No I wasn't. Although if anyone took time to read the 10q, the company has been lowering prices on levothyrine. The idea that they have been raising prices is not accurate. And like all drug companies, what happens is over time new drugs get approved and become a bigger part of sales while others because less sales. LCI constantly is have drugs approved left and right and a ton in the pipeline. I'm not worried about the piece in my opinion.
Market Data 
Markets 
AI
